Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal

Publikationen

Suchbegriffe: SORAFENIB, . Treffer: 30

2019

Franck, C; Rosania, R; Franke, S; Haybaeck, J; Canbay, A; Venerito, M The BRAF Status May Predict Response to Sorafenib in Gastrointestinal Stromal Tumors Resistant to Imatinib, Sunitinib, and Regorafenib: Case Series and Review of the Literature.
Digestion. 2019; 99(2):179-184
Web of Science PubMed FullText FullText_MUG

 

Scheipl, S; Liegl-Atzwanger, B; Szkandera, J; Rinner, B; Viertler, C; Friesenbichler, J; Bergovec, M; Leithner, A [Is there a magic bullet for sarcomas? : Personalised treatment for maligant tumours of bone and soft tissue].
Orthopade. 2019; 48(9): 776-783. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2018

Apostolidis, L; Pfeiffenberger, J; Gotthardt, D; Radeleff, B; Mehrabi, A; Schemmer, P; Jager, D; Schirmacher, P; Stremmel, W; Schulze-Bergkamen, H; Springfeld, C; Weiss, KH Survival of Hepatocellular Carcinoma Patients Treated with Sorafenib beyond Progression
GASTROINTEST TUMORS. 2018; 5(1-2): 38-46. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Li, M; Su, Y; Zhang, F; Chen, K; Xu, X; Xu, L; Zhou, J; Wang, W A dual-targeting reconstituted high density lipoprotein leveraging the synergy of sorafenib and antimiRNA21 for enhanced hepatocellular carcinoma therapy.
Acta Biomater. 2018; 75: 413-426.
Web of Science PubMed FullText FullText_MUG

 

Pearson, H; Knisely, AS; Deheragoda, M; Zacharoulis, S; Carceller, F Treatment of metastatic hepatocellular carcinoma in pediatric patients: Two case reports.
PEDIATR HEMAT ONCOL. 2018; 35(1): 90-94.
Web of Science PubMed FullText FullText_MUG

 

Schneider, C; Wallner, M; Kolesnik, E; Herbst, V; Mächler, H; Pichler, M; von Lewinski, D; Sedej, S; Rainer, PP The Anti-Cancer Multikinase Inhibitor Sorafenib Impairs Cardiac Contractility by Reducing Phospholamban Phosphorylation and Sarcoplasmic Calcium Transients.
Sci Rep. 2018; 8(1):5295-5295 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2017

Ganten, TM; Stauber, RE; Schott, E; Malfertheiner, P; Buder, R; Galle, PR; Göhler, T; Walther, M; Koschny, R; Gerken, G Sorafenib in Patients with Hepatocellular Carcinoma-Results of the Observational INSIGHT Study.
Clin Cancer Res. 2017; 23(19):5720-5728 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Lin, S; Hoffmann, K; Gao, C; Petrulionis, M; Herr, I; Schemmer, P Melatonin promotes sorafenib-induced apoptosis through synergistic activation of JNK/c-jun pathway in human hepatocellular carcinoma.
J PINEAL RES. 2017; 62(3):
Web of Science PubMed FullText FullText_MUG

 

2016

Jeric, I; Maurer, G; Cavallo, AL; Raguz, J; Desideri, E; Tarkowski, B; Parrini, M; Fischer, I; Zatloukal, K; Baccarini, M A cell-autonomous tumour suppressor role of RAF1 in hepatocarcinogenesis.
Nat Commun. 2016; 7(12):13781-13781 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pehserl, AM; Ress, AL; Stanzer, S; Resel, M; Karbiener, M; Stadelmeyer, E; Stiegelbauer, V; Gerger, A; Mayr, C; Scheideler, M; Hutterer, GC; Bauernhofer, T; Kiesslich, T; Pichler, M Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells.
Int J Mol Sci. 2016; 17(12): [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2015

Hoffmann, K; Ganten, T; Gotthardtp, D; Radeleff, B; Settmacher, U; Kollmar, O; Nadalin, S; Karapanagiotou-Schenkel, I; von Kalle, C; Jäger, D; Büchler, MW; Schemmer, P Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
BMC Cancer. 2015; 15(11):392-392 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Stotz, M; Gerger, A; Haybaeck, J; Kiesslich, T; Bullock, MD; Pichler, M Molecular Targeted Therapies in Hepatocellular Carcinoma: Past, Present and Future.
Anticancer Res. 2015; 35(11):5737-5744
Web of Science PubMed

 

2014

Brämswig, K; Ploner, F; Martel, A; Bauernhofer, T; Hilbe, W; Kühr, T; Leitgeb, C; Mlineritsch, B; Petzer, A; Seebacher, V; Stöger, H; Girschikofsky, M; Hochreiner, G; Ressler, S; Romeder, F; Wöll, E; Brodowicz, T Sorafenib in advanced, heavily pretreated patients with soft tissue sarcomas.
Anticancer Drugs. 2014; 25(7):848-853
Web of Science PubMed FullText FullText_MUG

 

Smolle, E; Taucher, V; Petru, E; Haybaeck, J Targeted treatment of ovarian cancer--the multiple - kinase - inhibitor sorafenib as a potential option.
Anticancer Res. 2014; 34(4):1519-1530
Web of Science PubMed

 

Walter, I; Wolfesberger, B; Miller, I; Mair, G; Burger, S; Gallè, B; Steinborn, R Human osteosarcoma cells respond to sorafenib chemotherapy by downregulation of the tumor progression factors S100A4, CXCR4 and the oncogene FOS.
Oncol Rep. 2014; 31(3):1147-1156 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2013

Degen, A; Weichenthal, M; Ugurel, S; Trefzer, U; Kilian, K; Garbe, C; Egberts, F; Poppe, LM; Hauschild, A; Gutzmer, R Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
J Dtsch Dermatol Ges. 2013; 11(9):846-853
Web of Science PubMed FullText FullText_MUG

 

Eisner, F; Schaberl-Moser, R; Gerger, A; Samonigg, H; Pichler, M Successful use of sorafenib after bortezomib failure in metastatic follicular thyroid cancer - a case report.
Onkologie. 2013; 36(6):368-370 (- Case Report)
Web of Science PubMed FullText FullText_MUG

 

Pfeiffenberger, J; Koschny, R; Hoffmann, K; Mehrabi, A; Schmitz, A; Radeleff, B; Stremmel, W; Schemmer, P; Ganten, TM Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation.
Langenbecks Arch Surg. 2013; 398(8):1123-1128
Web of Science PubMed FullText FullText_MUG

 

2012

Lin, S; Hoffmann, K; Schemmer, P Treatment of hepatocellular carcinoma: a systematic review.
Liver Cancer. 2012; 1(3-4):144-158 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2011

Egberts, F; Gutzmer, R; Ugurel, S; Becker, JC; Trefzer, U; Degen, A; Schenck, F; Frey, L; Wilhelm, T; Hassel, JC; Schadendorf, D; Livingstone, E; Mauch, C; Garbe, C; Berking, C; Rass, K; Mohr, P; Kaehler, KC; Weichenthal, M; Hauschild, A Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Ann Oncol. 2011; 22(7):1667-1674 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

Gerger, A; Labonte, M; Lenz, HJ Molecular predictors of response to antiangiogenesis therapies.
Cancer J. 2011; 17(2):134-141
Web of Science PubMed FullText FullText_MUG

 

Karki, P; Li, X; Schrama, D; Fliegel, L B-Raf Associates with and Activates the NHE1 Isoform of the Na+/H+ Exchanger.
J Biol Chem. 2011; 286(15): 13096-13105. [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pinter, M; Sieghart, W; Hucke, F; Graziadei, I; Vogel, W; Maieron, A; Königsberg, R; Weissmann, A; Kornek, G; Matejka, J; Stauber, R; Buder, R; Grünberger, B; Schöniger-Hekele, M; Müller, C; Peck-Radosavljevic, M Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
Aliment Pharmacol Ther. 2011; 34(8): 949-959. [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2010

Hoffmann, K; Franz, C; Xiao, Z; Mohr, E; Serba, S; Büchler, MW; Schemmer, P Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Anticancer Res. 2010; 30(11):4503-4508
Web of Science PubMed

 

Rausch, V; Liu, L; Kallifatidis, G; Baumann, B; Mattern, J; Gladkich, J; Wirth, T; Schemmer, P; Büchler, MW; Zöller, M; Salnikov, AV; Herr, I Synergistic activity of sorafenib and sulforaphane abolishes pancreatic cancer stem cell characteristics.
Cancer Res. 2010; 70(12):5004-5013 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

2009

Houben, R; Voigt, H; Noelke, C; Hofmeister, V; Becker, JC; Schrama, D MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib.
Mol Cancer Ther. 2009; 8(2):433-440 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG Google Scholar

 

Ploner, F; Eisterer, W Treatment of extensive disease
Wien Med Wochenschr. 2009; 159(15-16): 403-407.
PubMed FullText FullText_MUG

 

2008

Bhojani, N; Jeldres, C; Patard, JJ; Perrotte, P; Suardi, N; Hutterer, G; Patenaude, F; Oudard, S; Karakiewicz, PI Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.
Eur Urol. 2008; 53(5):917-930
Web of Science PubMed FullText FullText_MUG

 

Hoffmann, K; Glimm, H; Radeleff, B; Richter, G; Heining, C; Schenkel, I; Zahlten-Hinguranage, A; Schirrmacher, P; Schmidt, J; Büchler, MW; Jaeger, D; von Kalle, C; Schemmer, P Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation - HeiLivCa [ISRCTN24081794].
BMC Cancer. 2008; 8(3):349-349 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Pföhler, C; Ugurel, S Cutaneous reactions to molecular targeted therapies.
Hautarzt. 2008; 59(10):814-820
Web of Science PubMed FullText FullText_MUG

 

© Med Uni Graz Impressum